| scholarly article | Q13442814 |
| P50 | author | Helen McShane | Q58870907 |
| Lisa Stockdale | Q87705741 | ||
| Michael Riste | Q90313329 | ||
| Zita-Rose Manjaly Thomas | Q91643221 | ||
| Alison M. Lawrie | Q109926029 | ||
| P2093 | author name string | Morven Wilkie | |
| Iman Satti | |||
| Stephanie A Harris | |||
| Ali Hamidi | |||
| Alice Minhinnick | |||
| Raquel Lopez Ramon | |||
| Samantha Vermaak | |||
| Julia L Marshall | |||
| Henry Bettinson | |||
| P2860 | cites work | The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature | Q52877396 |
| Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination. | Q55617820 | ||
| Phase 2b Controlled Trial of M72/AS01 Vaccine to Prevent Tuberculosis | Q57069957 | ||
| IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge | Q58518610 | ||
| Immunization Against Measles by Aerosol | Q70272393 | ||
| Hypersensitivity Pneumonitis: A Comprehensive Review | Q26796700 | ||
| Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major | Q29619125 | ||
| Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial | Q29620144 | ||
| Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery | Q33603206 | ||
| Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial. | Q34259027 | ||
| Cough aerosols of Mycobacterium tuberculosis predict new infection: a household contact study | Q34322008 | ||
| Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature | Q34349749 | ||
| Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans | Q34361636 | ||
| Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis | Q34975770 | ||
| Cell-mediated immune responses in tuberculosis | Q34982062 | ||
| A "prime-pull" vaccine strategy has a modest effect on local and systemic antibody responses to HIV gp140 in mice | Q35049110 | ||
| New aspects of hypersensitivity pneumonitis. | Q35865633 | ||
| Evaluation of the Immunogenicity of Mycobacterium bovis BCG Delivered by Aerosol to the Lungs of Macaques | Q35998753 | ||
| Characterization of the Antigen-Specific CD4(+) T Cell Response Induced by Prime-Boost Strategies with CAF01 and CpG Adjuvants Administered by the Intranasal and Subcutaneous Routes | Q36002296 | ||
| A vaccine strategy that protects against genital herpes by establishing local memory T cells | Q36403540 | ||
| T-cell activation is an immune correlate of risk in BCG vaccinated infants | Q36799172 | ||
| Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques | Q36826315 | ||
| Immunogenicity and safety of aerosolized measles vaccine: systematic review and meta-analysis | Q37032973 | ||
| Hypersensitivity pneumonitis: insights in diagnosis and pathobiology | Q38017165 | ||
| Chronic hypersensitivity pneumonitis: important considerations in the work-up of this fibrotic lung disease | Q38316859 | ||
| Alternative routes of measles immunization: a review | Q38958647 | ||
| Vaccine-induced Th17 cells are established as resident memory cells in the lung and promote local IgA responses | Q40726914 | ||
| THE MOST RECENT EXPERIMENTS WITH "BACILLE CALMETTE GUERIN". | Q40845874 | ||
| Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns | Q41775340 | ||
| Control of chronic mycobacterium tuberculosis infection by CD4 KLRG1- IL-2-secreting central memory cells | Q42262934 | ||
| Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara | Q45722508 | ||
| BCG vaccination and the EPI. | Q46272168 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | tuberculosis | Q12204 |
| phase I clinical trial | Q5452194 | ||
| P304 | page(s) | e1002790 | |
| P577 | publication date | 2019-04-30 | |
| P1433 | published in | PLOS MEDICINE | Q1686921 |
| P1476 | title | Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial | |
| P478 | volume | 16 |
| Q64080155 | Addressing critical needs in the fight to end tuberculosis with innovative tools and strategies |
| Q97553095 | Emerging trends in inhaled drug delivery |
| Q92645553 | Insights and challenges in tuberculosis vaccine development |
| Q92246549 | Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges |
| Q98465670 | Targeting Unconventional Host Components for Vaccination-Induced Protection Against TB |
| Q89514589 | The status of tuberculosis vaccine development |
| Q89533499 | Toll like-receptor agonist Pam3Cys modulates the immunogenicity of liposomes containing the tuberculosis vaccine candidate H56 |
| Q90345218 | Vaccination Against Tuberculosis: Revamping BCG by Molecular Genetics Guided by Immunology |
| Q100751549 | Vaccine strategies for the Mtb/HIV copandemic |
Search more.